AI-generated summary
The authors studied red (660 nm) and near-infrared (810 nm) light therapy in differentiated SH-SY5Y cells exposed to amyloid-beta 42. They report that 810 nm treatment reduced amyloid aggregation, neurite retraction and cell death and restored acetylcholine levels. These are in vitro cell results, so they may not apply to people with Alzheimer's disease.
- Who or what was studied
- Differentiated SH-SY5Y cells (in vitro model) exposed to amyloid-beta 42
- Wavelengths
- 660, 810 nm
- Limits stated in the abstract
- The study used an in vitro cell model only, and the abstract does not report human data or any clinical validation.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 810 nm
- Energy density (fluence)
- 3 J/cm2
- Power density (irradiance)
- 5 mW/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Retraction, Cognitive decline. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.